Skip to main content

Table 1 Echocardiographic parameters

From: Succinate causes pathological cardiomyocyte hypertrophy through GPR91 activation

Parameter Control (n = 6) Control + Losartan (n = 3) Succinate (n = 8) Suc + Losartan (n = 5)
Cardiac output (mL/min) 52.17 ± 5.029 52.67 ± 4.7 68.03 ± 2.9* 56.14 ± 3.12
LV ejection fraction (%) 71.74 ± 3.02 75.43 ± 1.78 74.00 ± 1 71.76 ± 1.00
LV fraction shortening (%) 40.95 ± 2.57 45.20 ± 1.81 43.42 ± 0.9 41.87 ± 0.87
LVd (μL) 180.00 ± 9.7 203.90 ± 8.5 245.20 ± 10.11# 209.30 ± 12.09
LV systolic volume (μL) 72.98 ± 6.34 44.64 ± 7.31 62.70 ± 7.53 57.06 ± 3.9
Stroke volume (μl) 136.70 ± 12.63 137.20 ± 12.99 167.50 ± 7.34# 142.10 ± 6.9
Heart rate (bpm) 398.00 ± 9.2 399.40 ± 10.19 402.90 ± 7.9 393.60 ± 17.18
LVIDd (mm) 6.15 ± 0.22 6.32 ± 0.11 6.99 ± 0.09# 6.50 ± 0.15&
LVIDs (mm) 3.02 ± 0.06 3.49 ± 0.14 3.96 ± 0.10# 3.70 ± 0.10*
  1. *p < 0.05 versus control.
  2. &p < 0.05 versus succinate.
  3. #p < 0.01 versus control.